Jasper Therapeutics fell 54% after revealing a faulty batch of Briquilimab skewed trial results, prompting downgrades from BMO, Cantor, and others. Development in asthma is halted, and Phase 2b for CSU is delayed. Despite this, retail investors called it an "overreaction," with bullish sentiment and hopes for a rebound.